To the Editor The MONARCH 2 trial1 compared fulvestrant in combination with abemaciclib or placebo in patients with hormone receptor–positive, ERBB2-negative advanced breast cancer after progression to a prior endocrine therapy. Sledge and colleagues concluded that greater benefits were found in subgroups of patients with visceral metastasis and primary endocrine therapy resistance. This statement is based on earlier separation of the graphical curves and a numerically larger effect observed in overall survival (OS). However, no statistical interaction was presented in these subsets.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gil-Sierra MD, Briceño-Casado MDP, Fénix-Caballero S. Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer. JAMA Oncol. 2020;6(7):1122. doi:10.1001/jamaoncol.2020.1516
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: